Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
Taishan, CN
Teyi Pharmaceutical Group Co., Ltd. is a Chinese pharmaceutical company that focuses on the development, production, and sale of a broad range of medicinal products within China. Its offerings include both proprietary traditional Chinese medicines (TCMs) and various chemical products, such as finished preparations, raw materials, and other related chemical compounds. The company's portfolio of finished drugs targets several key therapeutic areas, including respiratory conditions (like cough and phlegm), kidney-related ailments, infectious diseases, cardiovascular issues, and digestive system disorders. Beyond finished medications, Teyi Pharmaceutical also supplies a variety of chemical raw materials and products; notable examples include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth and citric acid series compounds, and zinc sulfate. Based in Taishan, China, the company underwent a name change in November 2016, transitioning from its previous identity as Guangdong Taicheng Pharmaceutical Co., Ltd. to its current name, Teyi Pharmaceutical Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.37% | -1.34% | -10.88% | -28.28% | -36.83% | -18.43% | +3.39% | -29.59% | -4.43% | -21.68% | +72.18% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+33.1% ★ Q1'26: -28.9% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+300.0% ★ Q1'26: -16.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.5% Q1'26: -0.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.5% Q1'26: +17.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.4% Q1'26: +5.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.5% ★ Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.88× ★ Q1'26: 2.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
516.54M
est: 378.13M (+36.6%)
|
655.86M
est: 410.01M (+60.0%)
|
921.12M
est: 378.13M (+143.6%)
|
632.70M
est: 410.01M (+54.3%)
|
758.16M
est: 887.00M (-14.5%)
|
886.57M
est: 887.00M (0.0%)
|
1.07B
est: 1.15B (-6.9%)
|
687.79M
est: 776.00M (-11.4%)
|
915.67M
est: 1.03B (-11.1%)
|
1.11B
1.11B – 1.11B
+7.3% YoY
|
1.33B
1.33B – 1.33B
+20.5% YoY
|
1.59B
1.59B – 1.59B
+19.3% YoY
|
| EBITDA |
114.14M
est: 100.40M (+13.7%)
|
155.05M
est: 108.86M (+42.4%)
|
288.69M
est: 100.40M (+187.5%)
|
147.52M
est: 108.86M (+35.5%)
|
228.24M
est: 235.51M (-3.1%)
|
278.45M
est: 235.51M (+18.2%)
|
369.91M
est: 304.27M (+21.6%)
|
92.30M
est: 195.06M (-52.7%)
|
147.31M
est: 258.78M (-43.1%)
|
277.75M
277.75M – 277.75M
+7.3% YoY
|
334.81M
334.81M – 334.81M
+20.5% YoY
|
399.41M
399.41M – 399.41M
+19.3% YoY
|
| EBIT |
99.29M
est: 73.34M (+35.4%)
|
122.73M
est: 79.52M (+54.3%)
|
243.07M
est: 73.34M (+231.5%)
|
96.49M
est: 79.52M (+21.3%)
|
176.94M
est: 172.03M (+2.9%)
|
225.93M
est: 172.03M (+31.3%)
|
309.80M
est: 222.26M (+39.4%)
|
27.94M
est: 140.34M (-80.1%)
|
77.98M
est: 186.19M (-58.1%)
|
199.84M
199.84M – 199.84M
+7.3% YoY
|
240.90M
240.90M – 240.90M
+20.5% YoY
|
287.38M
287.38M – 287.38M
+19.3% YoY
|
| Net Income |
81.11M
est: 125.48M (-35.4%)
|
94.78M
est: 134.24M (-29.4%)
|
171.71M
est: 125.48M (+36.8%)
|
43.82M
est: 134.24M (-67.4%)
|
126.92M
est: 209.13M (-39.3%)
|
178.20M
est: 209.13M (-14.8%)
|
253.18M
est: 261.68M (-3.2%)
|
20.50M
est: 19.98M (+2.6%)
|
81.67M
est: 102.41M (-20.3%)
|
144.88M
144.88M – 144.88M
+41.5% YoY
|
219.82M
219.82M – 219.82M
+51.7% YoY
|
289.76M
289.76M – 289.76M
+31.8% YoY
|
| SGA |
138.61M
est: 66.36M (+108.9%)
|
187.07M
est: 71.96M (+160.0%)
|
267.18M
est: 66.36M (+302.6%)
|
153.87M
est: 71.96M (+113.8%)
|
175.95M
est: 155.67M (+13.0%)
|
176.38M
est: 155.67M (+13.3%)
|
240.67M
est: 201.13M (+19.7%)
|
225.54M
est: 201.23M (+12.1%)
|
285.80M
est: 266.97M (+7.1%)
|
286.55M
286.55M – 286.55M
+7.3% YoY
|
345.41M
345.41M – 345.41M
+20.5% YoY
|
412.06M
412.06M – 412.06M
+19.3% YoY
|
| EPS |
0.21
est: 0.24 (-14.3%)
|
0.24
est: 0.26 (-8.4%)
|
0.43
est: 0.24 (+75.6%)
|
0.11
est: 0.26 (-58.0%)
|
0.32
est: 0.41 (-21.6%)
|
0.41
est: 0.41 (+0.5%)
|
0.55
est: 0.51 (+7.7%)
|
0.04
est: 0.04 (+0.0%)
|
0.16
est: 0.21 (-22.0%)
|
0.29
0.29 – 0.29
+41.5% YoY
|
0.44
0.44 – 0.44
+51.7% YoY
|
0.58
0.58 – 0.58
+31.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bi Jian Cai | Accounting Supervisor | — | — |
| Danqing Xu | Chairman & GM | — | male |
| Songqing Xu | Deputy General Manager & Vice Chairman of The Board | — | male |
| Wei Cheng Wu | Deputy General Manager | — | male |
| Wen Ge Yan | Deputy General Manager | — | male |
| Xiliang Chen | Chief Financial Officer, Deputy GM, Board Secretary & Director | — | male |
| Yongzhao Zhang | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002728.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
